MV 004
Alternative Names: MV-004Latest Information Update: 05 Feb 2024
At a glance
- Originator MV BioTherapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Bacteria replacements; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Dysbiosis
Most Recent Events
- 21 Dec 2023 Preclinical trials in Cancer in Switzerland (unspecified route), prior to December 2023 (MV BioTherapeutics pipeline, December 2023)
- 21 Dec 2023 Preclinical trials in Dysbiosis in Switzerland (unspecified route), prior to December 2023 (MV BioTherapeutics pipeline, December 2023)